Psychiatric Outcomes After GLP-1RA vs Metformin in Hidradenitis Suppurativa Patients

A retrospective cohort of 309.2 weighted patients with hidradenitis suppurativa from the NIH All of Us Research Program compares psychiatric diagnosis rates after initiating GLP-1 receptor agonists versus metformin. The analysis, conducted by figshare admin karger and posted in April 2026, uses a new-user, active-comparator design with inverse probability of treatment weighting. At 12 months, psychiatric diagnoses occurred in 61.3% of GLP-1RA users versus 51.1% of metformin users, with a non-significant hazard ratio of 1.26.

Use Cases

• Compare psychiatric diagnosis risk between drug cohorts based on the reported 12-month incidence rates.
• Analyze time-to-event for psychiatric outcomes based on the reported hazard ratio and confidence interval.
• Study confounding adjustment methods in observational studies based on the use of stabilized inverse probability of treatment weighting.
• Investigate comorbidity patterns in hidradenitis suppurativa based on the described association with obesity and psychiatric conditions.

Strengths

• Study design includes a 365-day washout period and active comparator to reduce bias.
• Results include specific metrics: a 10.2 percentage point risk difference and a hazard ratio of 1.26 with 95% confidence intervals.
• Data is sourced from the NIH All of Us Research Program (Controlled Tier v8), a large-scale biomedical database.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 36.7 KB file size suggests the dataset is very small, containing summary results rather than individual patient records.

Provenance

Source

NIH All of Us Research Program (Controlled Tier v8)

Collection Method

Retrospective cohort study using a new-user, active-comparator design and SNOMED concepts for patient identification.

Freshness

Last updated 2026-04-24 09:55:10; freshness should be verified.